Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...
Health officials are downplaying the TB danger, although the outbreak has continued for a full year with no end in sight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback